NCT04474704

Use of Cheetah® Cardiac Monitoring System to Guide Discontinuation of Magnesium Sulfate in Women With Severe Preeclampsia

Use of Cheetah® Non-invasive Cardiac Monitoring System to Guide Discontinuation of Postpartum Magnesium Sulfate in Women With Severe Preeclampsia: A Pilot Randomized Control Trial

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 53 (actual)
• Sponsor: Ohio State University · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This is a single site pilot randomized, controlled, trial randomizing patients with PE with severe features to one of 2 groups: * 24 hours of postpartum magnesium sulfate (current arbitrary standard of care) * Using the Cheetah® device to aid in an individualized duration of magnesium sulfate.

Conditions

• Preeclampsia With Severe Features

Interventions

Type	Name	Description
DEVICE	Cheetah® non-invasive cardiac monitoring system	Cheetah® non-invasive cardiac monitor system will be used to individually determine the duration of magnesium sulfate postpartum (guided by timing of reduction in Systemic Vascular Resistance (SVR))
OTHER	Standard of care	24 hours of postpartum magnesium sulfate

Timeline

• Start date: 2021-02-22
• Primary completion: 2022-04-01
• Completion: 2022-05-31
• First posted: 2020-07-17
• Last updated: 2023-06-28
• Results posted: 2023-06-28

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated device study